GlycoMimetics (GLYC) Given Media Impact Rating of 0.16

Press coverage about GlycoMimetics (NASDAQ:GLYC) has trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlycoMimetics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.5019798380446 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several equities analysts recently issued reports on GLYC shares. Zacks Investment Research downgraded shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research note on Thursday, July 20th. Stifel Nicolaus reissued a “buy” rating and set a $17.00 price objective (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. BidaskClub raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity reissued a “buy” rating and set a $12.00 price objective on shares of GlycoMimetics in a research note on Friday, May 19th. Finally, Cowen and Company reissued an “outperform” rating on shares of GlycoMimetics in a research note on Sunday, May 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.20.

GlycoMimetics (NASDAQ:GLYC) opened at 10.74 on Friday. The firm’s 50-day moving average is $11.45 and its 200-day moving average is $8.17. GlycoMimetics has a 1-year low of $3.82 and a 1-year high of $16.94. The stock’s market cap is $351.45 million.

GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. On average, analysts forecast that GlycoMimetics will post ($1.22) EPS for the current year.

In related news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $15.57, for a total transaction of $31,140.00. Following the transaction, the senior vice president now directly owns 152,615 shares of the company’s stock, valued at $2,376,215.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 43.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “GlycoMimetics (GLYC) Given Media Impact Rating of 0.16” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply